Please assess the completion status of the following clinical trial:

Trial Title: Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Healthy volunteers, between 18 and 45 years of age~* Normal laboratory (blood test) results~Key Exclusion Criteria:~* Prior immunization with anthrax vaccine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- AVP-21D9 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).